First and second trimester maternal serum markers in pregnancies with a vanishing twin

Prenatal Diagnosis

Volumn 35, Issue 1, 2015, Pages 90-96

  Huang, Tianhua ^a   Boucher, Karen ^a   Aul, Ritu ^a,b   Rashid, Shamim ^a   Meschino, Wendy S ^a,b  

^a NORTH YORK GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN; DIMERIC INHIBIN A; ESTRIOL; INHIBIN A; PREGNANCY ASSOCIATED PLASMA PROTEIN A; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CONTROLLED STUDY; CROWN RUMP LENGTH; DOWN SYNDROME; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL SERUM; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING; SECOND TRIMESTER PREGNANCY; SPONTANEOUS TWIN TO SINGLETON REDUCTION; TWIN PREGNANCY; VANISHING TWIN; ADULT; BLOOD; FEMALE; FETUS RESORPTION; PREGNANCY; PROCEDURES;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; DOWN SYNDROME; FEMALE; FETAL RESORPTION; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PREGNANCY, TWIN; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; RETROSPECTIVE STUDIES;

EID: 84921507643     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4492     Document Type: Article

References (25)

1. Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353:2001-11.
2. Guanciali-Franchi P, Iezzi I, Soranno A, et al. Optimal cut-offs for Down syndrome contingent screening in a population of 10, 156 pregnant women. Prenat Diagn 2012;32:1147-50.
3. Okun N, Summers AM, Hoffman B, et al. Prospective experience with integrated prenatal screening and first trimester combined screening for trisomy 21 in a large Canadian urban center. Prenat Diagn 2008;28:987-92.
4. Wald NJ, Rodeck C, Hackshaw AK, et al. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10(2):56-104.
5. Spencer K, Nicolaides KH. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. BJOG 2003;110:276-80.
6. Spencer K, Kagan KO, Nicolaides KH. Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers. Prenat Diagn 2008;28:49-52.
7. Spencer K, Staboulidou I, Nicolaides KH. First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers. Prenat Diagn 2010;30:235-40
8. Sankaran S, Rozette C, Dean J, et al. Screening in the presence of a vanished twin: nuchal translucency or combined screening test? Prenat Diagn 2011;31:600-1.
9. Chasen ST, Perni SC, Predanic M, et al. Does a "vanishing twin" affect first-trimester biochemistry in Down syndrome risk assessment? Am J Obstet Gynecol 2006;195:236-9.
10. Gjerris AC, Loft A, Pinborg A, et al. The effect of a 'vanishing twin' on biochemical and ultrasound first trimester screening markers for Down's syndrome in pregnancies conceived by assisted reproductive technology. Hum Reprod 2009;24:55-62.
11. Daya S. Accuracy of gestational age estimation by means of fetal crown-rump length measurement. Am J Obstet Gynecol 1993;168(3 Pt 1):903-8.
12. Bischof P, Amandruz M, Weil-Franck C. et al. The disappearance rate of pregnancy-associated plasma protein-A (PAPP-A) after the end of normal and abnormal pregnancies. Arch Gynecol 1984;236:93-8.
13. Korhonen J, Alfthan H, Ylöstalo P, et al. Disappearance of human chorionic gonadotropin and its alpha- and beta-subunits after term pregnancy. Clin Chem 1997;43:2155-63.
14. Brady PC, Correia KF, Missmer SA, et al. Early β-human chorionic gonadotropin trends in vanishing twin pregnancies. Fertil Steril 2013;100:116-21.
15. Abbas A, Johnson M, Bersinger N, et al. Maternal alpha-fetoprotein levels in multiple pregnancies. Br J Obstet Gynaecol 1994;101:156-8.
16. Rotmensch S, Celentano C, Shalev J, et al. Midtrimester maternal serum screening after multifetal pregnancy reduction in pregnancies conceived by in vitro fertilization. J Assist Reprod Genet 1999;16:8-12.
17. Johnson MR, Abbas A, Nicolaides KH. Maternal plasma levels of human chorionic gonadotrophin, oestradiol and progesterone in multifetal pregnancies before and after fetal reduction. J Endocrinol 1994;143:309-12.
18. Chen HJ, Huang LW, Lin YH, et al. Midtrimester maternal serum inhibin A levels after multifetal pregnancy reduction. Prenat Diagn 2007;27:431-4.
19. Bredow MT, Goldie DJ. Rapid falls in maternal serum alpha-fetoprotein concentrations. J Clin Pathol 1985;38:473-4.
20. Muttukrishna S, Child TJ, Groome NP, et al. Source of circulating levels of inhibin A, pro alpha C-containing inhibins and activin A in early pregnancy. Hum Reprod 1997 May;12:1089-93.
21. Florio P, Luisi S, Ciarmela P, et al. Inhibins and activins in pregnancy. Mol Cell Endocrinol 2004;225:93-100.
22. Levitz M, Kadner S, Young BK. Intermediary metabolism of estriol in pregnancy. J Steroid Biochem 1984;20:971-4.
23. Wald NJ, White N, Morris JK, et al. Serum markers for Down's syndrome in women who have had in vitro fertilization: implications for antenatal screening. Br J Obstet Gynaecol 1999;106:1304-6
24. Lambert-Messerlian G, Palomaki GE, Canick JA. Adjustment of serum markers in first trimester screening. J Med Screen 2009;16:102-3
25. th International Prenatal Screening Group (IPSG) Congress: Barcelona, Spain, June 20-21, 2011.